Cargando…
Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
OBJECTIVE: Use of tacrolimus in mild to moderate myasthenia gravis (MG) is generally limited to glucocorticoid‐refractory cases; the advantage of mono‐tacrolimus over mono‐glucocorticoids is unknown. METHODS: We included mild to moderate MG patients treated with mono‐tacrolimus (mono‐TAC) or mono‐gl...
Autores principales: | Fan, Zhirong, Lei, Lin, Su, Shengyao, Zhang, Shu, Xie, Nairong, Li, Ling, Lu, Yan, Di, Li, Wang, Min, Xu, Min, Shen, Xin‐Ming, Da, Yuwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109324/ https://www.ncbi.nlm.nih.gov/pubmed/36808840 http://dx.doi.org/10.1002/acn3.51746 |
Ejemplares similares
-
Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020) -
Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis
por: Su, Shengyao, et al.
Publicado: (2022) -
VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis
por: Su, Shengyao, et al.
Publicado: (2021) -
Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis
por: Kim, Yool-hee, et al.
Publicado: (2019) -
The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis
por: Xie, Yanchen, et al.
Publicado: (2017)